HLB Pharmaceutical Co. Ltd
HLB Pharmaceutical Co., Ltd. researches and develops peptide drugs in South Korea. The company offers skeletal muscle relaxant, tranquilizers, antihistamines, antihypertensive agents, pain relief, antipruritics, astringents, anti-inflammatories, alimentary system drugs, metabolic drugs, ophthalmic agents, local anesthetics, antiarteriosclerotic agents, expectorants, antipyretics, analgesics, anti… Read more
Market Cap & Net Worth: HLB Pharmaceutical Co. Ltd (047920)
HLB Pharmaceutical Co. Ltd (KQ:047920) has a market capitalization of $338.02 Million (₩494.93 Billion) as of March 18, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #13251 globally and #341 in its home market, demonstrating a -0.07% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying HLB Pharmaceutical Co. Ltd's stock price ₩15090.00 by its total outstanding shares 32798775 (32.80 Million).
HLB Pharmaceutical Co. Ltd Market Cap History: 2015 to 2026
HLB Pharmaceutical Co. Ltd's market capitalization history from 2015 to 2026. Data shows growth from $157.55 Million to $338.02 Million (6.39% CAGR).
Index Memberships
HLB Pharmaceutical Co. Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$166.01 Billion | 0.17% | #112 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$166.01 Billion | 0.17% | #112 of 1384 |
Weight: HLB Pharmaceutical Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
HLB Pharmaceutical Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how HLB Pharmaceutical Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
HLB Pharmaceutical Co. Ltd's market cap is 0.00 times its annual revenue
1.01x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.27x
HLB Pharmaceutical Co. Ltd's market cap is 0.27 times its annual earnings
10.29x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $157.55 Million | $17.71 Billion | -$2.36 Billion | 0.01x | N/A |
| 2016 | $116.26 Million | $20.35 Billion | $577.41 Million | 0.01x | 0.20x |
| 2017 | $143.81 Million | $15.56 Billion | -$5.45 Billion | 0.01x | N/A |
| 2018 | $94.64 Million | $20.54 Billion | -$7.06 Billion | 0.00x | N/A |
| 2019 | $121.63 Million | $36.10 Billion | $472.65 Million | 0.00x | 0.26x |
| 2020 | $383.05 Million | $40.57 Billion | -$74.84 Billion | 0.01x | N/A |
| 2021 | $302.41 Million | $62.85 Billion | -$13.23 Billion | 0.00x | N/A |
| 2022 | $237.44 Million | $107.48 Billion | -$11.78 Billion | 0.00x | N/A |
| 2023 | $340.71 Million | $135.95 Billion | -$19.43 Billion | 0.00x | N/A |
| 2024 | $539.85 Million | $137.08 Billion | $2.02 Billion | 0.00x | 0.27x |
Competitor Companies of 047920 by Market Capitalization
Companies near HLB Pharmaceutical Co. Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to HLB Pharmaceutical Co. Ltd by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
HLB Pharmaceutical Co. Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, HLB Pharmaceutical Co. Ltd's market cap moved from $157.55 Million to $ 338.02 Million, with a yearly change of 6.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩338.02 Million | -5.92% |
| 2025 | ₩359.30 Million | -33.44% |
| 2024 | ₩539.85 Million | +58.45% |
| 2023 | ₩340.71 Million | +43.49% |
| 2022 | ₩237.44 Million | -21.48% |
| 2021 | ₩302.41 Million | -21.05% |
| 2020 | ₩383.05 Million | +214.92% |
| 2019 | ₩121.63 Million | +28.52% |
| 2018 | ₩94.64 Million | -34.19% |
| 2017 | ₩143.81 Million | +23.70% |
| 2016 | ₩116.26 Million | -26.21% |
| 2015 | ₩157.55 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of HLB Pharmaceutical Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $338.02 Million USD |
| MoneyControl | $338.02 Million USD |
| MarketWatch | $338.02 Million USD |
| marketcap.company | $338.02 Million USD |
| Reuters | $338.02 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.